Citadel Advisors’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding BBIO
Citadel Advisors's BBIO Position: Q3 2026 in Review
Citadel Advisors reduced its BridgeBio Pharma (BBIO) stake by 54% in Q3 2026, selling an estimated $158M and leaving 1,725,205 shares worth $114M. The position accounts for 0.01% of the portfolio, ranked #914.
Citadel Advisors first reported a position in BBIO in Q2 2019 and has held it in 26 quarters since. The position peaked at $280M in Q2 2026. 471 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.
- Citadel Advisors held 1,725,205 shares of BridgeBio Pharma worth $114M as of Q3 2026.
- Citadel Advisors sold 2,034,823 BridgeBio Pharma shares in Q3 2026, an estimated $158M.
- BridgeBio Pharma made up 0.01% of Citadel Advisors's portfolio in Q3 2026, its #914 holding.
- Citadel Advisors first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 26 quarters since.
- Citadel Advisors's BridgeBio Pharma position peaked at $280M in Q2 2026.
- 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.